SYSTEMATIC REVIEW article

Front. Pediatr., 16 February 2021

Sec. Children and Health

Volume 8 - 2020 | https://doi.org/10.3389/fped.2020.549549

Interventions for Addressing Anemia Among Children and Adolescents: An Overview of Systematic Reviews

  • 1. Department of Community Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India

  • 2. Division of Evidence Synthesis, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India

  • 3. Division of Reproductive, Maternal and Child Health, Indian Council of Medical Research, New Delhi, India

  • 4. Manipal Institute of Communication, Manipal Academy of Higher Education, Manipal, India

  • 5. Medical Biometrics & Informatics (Biostatistics), Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

  • 6. Department of Community Medicine, School of Epidemiology and Public Health, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India

Article metrics

View details

17

Citations

17,6k

Views

4k

Downloads

Abstract

Context: Anemia is a public health problem that can lead to growth, cognitive, and motor impairments.

Objective: To collate evidence on interventions for addressing childhood and adolescent anemia.

Methods: In this overview of systematic reviews, we included Cochrane as well as non-Cochrane systematic reviews (SRs) irrespective of language and publication status. Two sets of review authors independently screened articles for eligibility and extracted data from relevant SRs. We present data in a tabular format and summarize results based on outcome reported, age of participants, and type of interventions. We also adopt a “measurement for change” approach to assess the utility of measurement for development of interventions in childhood and adolescent anemia.

Results: Our search yielded 2,601 records of which 31 SRs were found eligible for inclusion. Results were favorable for fortification and supplementation with clear reduction in the risk of anemia and increase in hemoglobin levels across all age groups. Other interventions reported by the SRs were inconclusive and suggest further research.

Conclusions: Current evidence suggests that fortification or supplementation with iron and micronutrients leads to better reduction in the risk of anemia and improvements in hemoglobin levels among children and adolescents. Results of this overview can help decision makers in informing selection of interventions to address childhood and adolescent anemia.

Review Registration: PROSPERO CRD42016053687.

Introduction

Anemia is a condition in which there is either a decrease in the number of red blood corpuscles (RBCs) or a decrease in the total amount of hemoglobin (Hb) (1). The World Health Organization (WHO) defines childhood anemia as Hb concentration below 11 grams per deciliter in children between 6 and 59 months, below 11.5 grams per deciliter in children between 5 and 11 years, and below 12 grams per deciliter in children between 12 and 14 years of age (2).

The highest burden of anemia is in low- and middle-income countries (LMICs). Estimates show that almost 90,000 deaths have occurred due to iron deficiency anemia across all age groups (3). India, with ~89 million children with anemia is the highest contributor of childhood anemia (4, 5). Iron deficiency anemia is the most common cause of anemia on a global level. Other causes of childhood anemia include nutritional deficiencies, such as deficiency of folic acid, iron, or vitamin B12; chronic conditions, such as inflammatory disorders; and parasitic infestations (2). Disorders associated with synthesis of hemoglobin, formation of RBCs, or survival of RBCs are the other, less common causes of anemia in children (2). Malaria, HIV, tuberculosis, and helminthic infestations have been reported to lead to substantial burden of anemia, especially in developing countries (2, 6, 7). The severity of anemia is higher in children under 8 years old as compared with children over 8 years (8). Regardless of the etiology of anemia, impaired physical growth, motor development, and cognitive development have been observed in anemic children (7, 912).

WHO and the United Nations International Children's Emergency Fund (UNICEF) recommend multipronged public health preventive strategies, such as supplementation of nutrients, fortification of food with nutrients, educational interventions, and prevention and control of parasitic and protozoal infestations (13).

Our comprehensive search strategy reveals many systematic reviews (SRs) that assess the efficacy of different public health interventions for addressing childhood anemia. However, no synthesis of these reviews has been reported in an overview. Hence, the Indian Council of Medical Research (ICMR) task force on childhood and adolescent anemia commissioned this overview in order to collate evidence on the efficacy of various interventions in addressing childhood and adolescent anemia in order to inform programs and a future research agenda. This review could serve as a baseline for clinicians, stakeholders, and decision makers to intervene in childhood and adolescent anemia.

Methods

A letter of intent was invited from Indian scientists with experience in evidence synthesis. A review team of experienced researchers was constituted to work on the overview of SRs. The protocol was registered in the PROSPERO prospective register of systematic reviews (Registration number: CRD42016053687) after consultation with national experts (14).

Inclusion Criteria

Irrespective of language and publication status, we included SRs, evaluating the effect of

  • Any one intervention, or

  • Combination of interventions, such as iron of ferrous sulfate (FS) or zinc (Zn) or multi micro nutrients (MMN) or vitamin supplementation, or

  • Iron or FS or Zn or MMN or vitamin fortification, or

  • Anti-helminthic treatment

  • Treatment or prevention of malaria, or

  • Treatment of H. pylori, or

  • Water, sanitation, and hygiene (WASH) interventions.

We included SRs designed for addressing anemia in children between 6 months and 19 years of age. We included studies regardless of gender, study setting, and severity of anemia. We excluded non-SRs, SRs targeting populations other than children and adolescents, those done on overtly diseased children or adolescents, those providing data on overlapping age groups, and SRs that did not assess the outcomes of interest of this overview. We assessed outcomes, namely anemia, Hb levels, and adverse events.

Search Methods for Identification of Reviews

We searched the electronic sources listed below between February 8, 2018, and February 10, 2018, and further updated searches between January 5, 2019, and February 7, 2019: Cochrane Database for Systematic Reviews, MEDLINE via PubMed, Database of Abstracts of Reviews of Effects, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Excerpta Medica dataBASE (EMBASE), Campbell Collaboration Online Library of Systematic Reviews (www.campbellcollaboration.org/library.html), Database of Promoting Health Effectiveness Reviews (https://eppi.ioe.ac.uk/webdatabases4/Intro.aspx?ID=9), and 3ie Database of Systematic Reviews. The review team, in consultation with an information specialist (RV), decided potential key words to be used for this evidence summary. We developed the search strategy for CENTRAL as in Supplementary File 1. In addition, we hand-searched the bibliographies of all eligible reviews, pertinent clinical guidelines, and textbooks to find relevant reviews. We also communicated and requested specialists in this field to provide related unpublished work.

Selection of Reviews

We undertook screening of SRs using Covidence SR software (15). Two overview authors (PM and RH) independently screened all SRs (retrieved in the search process) on the basis of title and abstract. Two overview authors (RH and NK) then independently screened the full texts of identified reviews for inclusion. A third reviewer (BU) resolved disagreement among primary reviewers through discussion. We prepared a PRISMA flow diagram to map the inclusion and exclusion of SRs (16).

Data Extraction

We developed and pilot-tested our data extraction form for its suitability and usability. Three review authors (AS, PM, and NK) independently extracted data regarding characteristics of the included participants, interventions, comparisons, outcomes, and methodological quality of the included reviews. We contacted reviewers to seek missing information if any.

Methodological Quality of Included Reviews Summarized in the Overview

Two review authors (AS and PM) independently evaluated the methodological quality of included reviews with the Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) tool (17, 18).

Data Synthesis

We followed standard procedures given by the Cochrane Handbook for Systematic Reviews of Interventions (19). We obtained data from included SRs and presented them in a tabular and graphical format. In case of duplicate publications, we considered them as a single report. We summarized results based on outcome reported, age of participants, and type of interventions as risk ratio (RR), mean difference (MD), standardized mean difference (SMD), or weighted mean difference (WMD) with 95% confidence intervals (95% CI). As an overview, we mainly focused on summarizing and thematically categorizing the intervention and its effectiveness and not taking a more interpretative approach during synthesis.

Results

Search Results

Our search yielded 2,601 records. After removal of duplicates, 2,204 records remained, and they were screened for title and abstract. At this stage, we excluded 2,043 articles, and a total of 161 full-text articles were screened for eligibility. We excluded 130 articles and included 31 SRs that met our inclusion criteria (Figure 1).

Figure 1

Figure 1

Preferred reporting items for SR and meta-analysis: the PRISMA flow diagram for inclusion and exclusion of studies.

Description of Included Reviews

We included 31 SRs in this overview, the salient features of which are depicted in Table 1.

Table 1

SNStudy IDNo of trials/Sample sizeParticipantsInterventionOutcomes reported
SUPPLEMENTATION
1.Low et al. (20)10–50 years age: 67/8,506
12–18 years age: 10/3,220
Menstruating women aged 10–50 years
Subgroup analysis done for 12–18 years
Daily oral iron supplementation with or without other vitamins (folic acid or vitamin C)Anemia
Hemoglobin
Biomarkers (Ferritin)
2.Neuberger et al. (21)35/31,955<18 years children in malaria-endemic areas ± anemia ± malariaIron, iron + folic acid, and iron + antimalarialAnemia
Hemoglobin
Adverse effects
3.Mayo-Wilson et al. (22)80/2,05,4016 months to 12 years of ageOrally administered zinc supplementation and non-zinc co-interventions (e.g., vitamin A, additional iron)Anemia
Hemoglobin
Adverse effects
Biomarkers (Fe)
4.Cembranel et al. (23)13/1,699Children <5 years of ageWeekly/daily supplementation of ironAnemia
Hemoglobin
5.Low et al. (24)32/7,089Children between 3.3 and 15 years of ageIron supplementationAnemia
Hemoglobin
Adverse effects
Biomarkers (Ferritin)
6.Pasricha et al. (25)33/42,0154–23 months of ageDaily iron supplementationAnemia
Hemoglobin
Adverse effects
Biomarkers (Ferritin, iron, transferrin, erythrocyte protoporphyrin)
7.Thompson et al. (26)15/2,1542–5 yearsDaily oral iron supplementationHemoglobin
Biomarkers (Ferritin)
8.Abdullah et al. (27)2/696–30 monthsOral ferrous glycine sulfate and ferrous sulfateMA not done due to high heterogeneity
9.De-Regil et al. (28)33/13,114Apparently healthy children <12 yearsIntermittent oral iron supplementation alone or in combination with other vitamins and mineralsAnemia
Hemoglobin
Adverse effects
Biomarkers (Ferritin)
10.Ramakrishnan et al. (29)21/4,6516 month to 18 yearsIron interventionsHemoglobin
FORTIFICATION
11.Matsuyama et al. (30)15 articles based on 12 studies/NRHealthy children aged 6–47 monthsFortified milkAnemia
Hemoglobin
Biomarkers (Serum Ferritin, serum transferrin receptor concentration)
12.De-Regil et al. (31)13 trials (17 reports)/5,810Preschool and school-age children from Latin America, Africa, and AsiaPoint-of-use fortification of foods with MNPAnemia
Hemoglobin
Adverse effects
Biomarkers (Ferritin)
13.Aaron et al. (32)1050525 apparently healthy children and women of reproductive age from LMICsNon-dairy MMN fortified beveragesAnemia
14.Das et al. (33)11Children and women (presented separate data for children)
<11 year old children, pre-term infants, malnourished infants, and school children with asymptomatic zinc deficiency)
Zinc fortified formula feedsHemoglobin
15.Das et al. (34)201 (121 on infants and children)Children <18 years of age and women (presented separate data for infants and children)Vitamin A, iron and multiple micronutrients fortified formula foodAnemia
Hemoglobin
Biomarkers (Ferritin)
16.Salam et al. (35)17Women and children (6–66 months of age) (no studies identified on women)Point-of-use powders with ≥2 micronutrients in their formulation (Vit A, C, B 11, D, B complex, Fe, Zinc, lysine)Anemia
Hemoglobin
Biomarkers (Ferritin)
17.Eichler et al. (36)18/5,4686 months to 5 yearsMicro-nutrient fortified milk or cereal foodAnemia
Hemoglobin
Biomarkers (Ferritin)
18.Gera et al. (37)60/20,827Apparently healthy individuals, irrespective of age. Reported separate data for children on HbIron-fortified foodsHemoglobin
19.De-Regil et al. (38)Home fortification with multiple micronutrient powders
20.Best et al. (39)12/6,145Children between 5.5 and 18 yearsMinimum 3 micronutrients added to beverages, foodsNot done
21.Dewey et al. (40)16/6,113Children between 6 months and 2 yearsSprinkles, Crushable, or chewable tablets, Lipid-based nutrient supplements, soya based products.Anemia
Hemoglobin
Adverse events
Biomarkers (Ferritin)
SUPPLEMENTATION WITH FORTIFICATION
22.Kristjansson et al. (41)323 months to 5 years socio-economically disadvantaged LMIC and HICsMacronutrient supplementation/fortificationAnemia
Hemoglobin
23.McDonagh et al. (42)10/5,671Children aged between 6 and 24 months from developed countriesOral iron supplementation, iron fortified formula, and foodMA not done
24.Gera et al. (43)30/6,464Birth to 15 yearsIron and multiple micronutrient supplementation ± fortificationHemoglobin
25.Gera et al. (44)55/27,945<18 years of ageIron supplementation, formula milk, fortified cerealsHemoglobin
26.Sun et al. (45)6/676Chinese children between 6 months and 13 years with iron deficiency anemia inDietary interventionsAnemia
DEWORMING
27.Taylor-Robinson et al. (46)45Children aged ≤ 16 years in areas endemic for intestinal helminthesDewormingHemoglobin
28.Girum et al. (47)810,05,239 school children from Asia and AfricaDewormingHemoglobin
H. PYLORITREATMENT
29.Huang et al. (48)8/4502–76 years (subgroup analysis available for children)H. pylori treatmentHemoglobin
Biomarkers (Ferritin)
WASH INTERVENTION
30.Dangour et al. (49)14/22,241<18 yearsWASH interventionHemoglobin (No MA)
Biomarkers (Ferritin) (No MA)
ANTI-MALARIA INTERVENTION
31.Athuman et al. (50)6/3847Anemic children between 2 months and 9 years residing in endemic areasIntermittent preventive antimalarial treatmentAnemia

Characteristics of the included systematic reviews.

We included nine Cochrane reviews (20, 21, 28, 31, 38, 41, 46, 49, 50) and 22 non-Cochrane SRs (2227, 29, 30, 3237, 39, 40, 4245, 47, 48). Except for Cembranel et al. (23), all other reviews are in the English language. Updating the version of existing SRs was reported only by Cochrane reviews. The review by Neuberger et al. (21) is the updated version of previous publications (51, 52). Taylor-Robinson et al. (46) is updated from a previous five Cochrane reviews (5355). One Cochrane review by De-Regil et al. (38) has been reprinted in a Cochrane review journal (56), and hence, to avoid duplication, we considered both reviews as a single report (38). Abdullah et al. (27), Best et al. (39), McDonagh et al. (42), and Dangour et al. (49) did not undertake meta-analysis.

Included reviews differed in the age groups of participants: 11 reviews included participants <5 years of age (23, 2527, 30, 33, 35, 36, 38, 40, 41). Low et al. (20), Das et al. (34), and Huang et al. (48) included participants of age groups beyond the inclusion range in our overview, but they reported separate data for children as a subgroup analysis and, hence, were included. Aaron et al. (32) included a trial on pregnant women that was not included in the meta-analysis of anemia. Another review (35) considered included women but did not identify studies on women and, hence, was included in this overview. Except for Low et al. (24), all included reviews included participants of both genders. All SRs except McDonagh et al. (42) included studies from LMICs and developing countries. Sun et al. (45) included specifically the Chinese population. One SR included studies each on children from malaria endemic areas (21), areas endemic for intestinal helminths (46), and areas endemic for anemia (50).

Reviews covered an array of interventions for prevention, control, and/or treatment of anemia in children and adolescents. We found 11 reviews on iron supplementation (2029, 44). Six reviews were on fortification (28, 30, 33, 35, 39, 57); five reviews on supplementation with fortification (4145); two reviews on deworming (46, 47); and one review each on H. pylori treatment (48), WASH intervention (49), and antimalarial intervention (50).

Effects of Interventions

Anemia

A total of 18 SRs addressed the effect of different interventions on anemia in children and adolescents (2025, 28, 3036, 40, 41, 45, 50) (Table 2 and Figure 2). We did not find any review that assessed the effect of treatment of deworming, H. pylori infection, or WASH intervention on anemia status.

Table 2

SR#Included studies#ParticipantsComparisonMeta-analysisQuality of evidence
INFANTS
Das et al. (34)Iron fortification61,234 infantsIron fortification verses unfortified foods/ regular dietRR (95%CI) = 0.42 (0.24, 0.72)Moderate
Das et al. (34)MMN fortification31,809 infantsMMN fortification verses unfortified foods/ regular dietRR (95%CI) = 0.59 (0.50, 0.70)Low
Matsuyama et al. (30)FortificationNRHealthy children <1 year of ageFortified milk verses controlOR (95%CI) = 0.46 (0.19, 1.12)NR
<2 YEARS
Pasricha et al. (25)Iron supplementation174,825 children between 4 and 23 monthsIron supplementation verses controlRR (95%CI) = 0.61 (0.50, 0.74)
P < 0.0001
I2 = 86%
NR
De-Regil et al. (38)Fortification61,447 children 6–23 monthsHome fortification with MMP verses placebo/no interventionRR (M-H, RE, 95%CI) = 0.69 (0.60–0.78), I2 = 19%Moderate
De-Regil et al. (38)Fortification1145 children 6–23 monthsHome fortification with multiple micronutrient powders verses iron supplementsRR (M-H, RE, 95%CI) = 0.89 (0.58–1.39)Low
Dewey et al. (40)Fortification4,331 children 6 months to 2 yearsHome fortification as prevention verses controlRR (95%CI) = 0.54 (0.46, 0.64)NR
Dewey et al. (40)Fortification1,263 children 6 months to 2 yearsHome fortification as treatment verses controlRR (95%CI) = 1.04 (0.76, 1.41)NR
<5 YEARS
Matsuyama et al. (30)FortificationNRHealthy children aged 6–47 months from all countriesFortified milk verses controlOR (95%CI) = 0.32 (0.15, 0.66)NR
Matsuyama et al. (30)FortificationNRHealthy children aged 6–47 months from developing economiesFortified milk verses controlOR (95%CI) = 0.36 (0.14, 0.91)NR
Eichler et al. (36)Iron + MMN fortification71,927 children between 6 months and 5 yearsIron + MMN fortification verses non-fortified foodRR (95%CI) = 0.43 (0.26–0.71)
P = 0.00
I2 = 80.5%
NR
Eichler et al. (36)Iron fortification113,100 children from 6 months to 5 years of ageIron fortification of milk and cereals verses non-fortified foodRR (95%CI) = 0.50 (0.33, 0.75)
I2 = 71.2%
NR
De-Regil et al. (31)MNP fortification61,706 children aged 24–59 monthsPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.64 (0.44, 0.93)
P = 0.019
I2 = 73%
NR
Eichler et al. (36)Iron fortification41,173 Children between 6 months and 5 yearsIron single-fortification verses controlRR (95%CI) = 0.76 (0.45–1.28)
P = 0.533
I2 = 0%
NR
Kristjansson et al. (41)Supplementation and fortification1 before-after studies110 children between 3 months and 5 years of ageSupplementary feeding verses controlOR (95%CI) = 0.58 (0.24, 0.75)NR
Cembranel et al. (23)FS supplementationChildren <5 yearsDaily doses of FS verses controlRR (95%CI) = 0.73 (0.49, 1.09), P = 0.13, I2 > 75%NR
Cembranel et al. (23)FS supplementationChildren <5 yearsWeekly doses of FS verses controlRR (95%CI) = 0.64 (0.27, 1.54), P = 0.33, I2 > 75%NR
Cembranel et al. (23)FS supplementationChildren <5 yearsDaily doses of FS verses weekly dosesRR (95%CI) = 0.70 (0.41, 1.19), P = 0.09NR
De-Regil et al. (28)Iron supplementation4658 apparently healthy children <5 yearsIntermittent iron supplements verses placeboRR (M-H, RE, 95% CI) = 0.43 (0.23, 0.80)NR
De-Regil et al. (28)Iron supplementation3770 apparently healthy children <5 yearsIntermittent iron supplements verses daily iron supplementsRR (M-H, RE, 95% CI) = 1.26 (1.05, 1.51)NR
PRE-SCHOOL AND SCHOOL-GOING CHILDREN
Das et al. (34)MMN Fortification51,246 pre-school and school-going childrenMMN fortification verses unfortified foods/regular dietRR (95%CI) = 0.45 (0.22, 0.89)Low
Das et al. (34)Iron Fortification102,013 pre-school and school-going childrenIron fortification verses unfortified foods/ regular dietRR (95%CI) = 0.60 (0.43, 0.84)Moderate
De-Regil et al. (31)Fortification102,448 pre-school and school-age childrenPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.66 (0.49–0.88)
P = 0.004
I2 = 73%
Moderate
De-Regil et al. (31)Fortification71,705 pre-school and school-age children with malariaPoint-of-use fortification of foods with iron+ vitamin A + zinc verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.72 (0.65, 0.80)
P = 0.47
I2 = 0%
NR
De-Regil et al. (31)Fortification4934 pre-school and school-age children with malariaPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.57 (0.29, 1.14)
P = 0.0005
I2 = 83%
NR
<12 YEARS
De-Regil et al. (28)Iron Supplementation101,824 apparently healthy children <12 yearsIntermittent iron supplements iron alone or with other nutrients verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.51 (0.37, 0.72)Moderate
De-Regil et al. (28)Iron Supplementation6980 apparently healthy children <12 yearsIntermittent iron supplements ± other micronutrients verses daily iron supplements ± other micronutrientsRR (M-H, RE, 95% CI) = 1.23 (1.04, 1.47)
P = 0.017
I2 = 0%
Low
De-Regil et al. (28)Iron Supplementation51,456 apparently healthy children <12 yearsIntermittent iron supplements (0–3 months duration) verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.63 (0.49, 0.82)NR
De-Regil et al. (28)Iron Supplementation5368 apparently healthy children <12 yearsIntermittent iron supplements (>3 months duration) verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.37 (0.14, 1.02)NR
De-Regil et al. (28)Iron Supplementation61074 apparently healthy children <12 yearsIntermittent iron alone supplements verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.48 (0.31, 0.74)NR
De-Regil et al. (28)Iron Supplementation2593 apparently healthy children <12 yearsIntermittent iron with folic acid supplements verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.83 (0.66, 1.03)NR
De-Regil et al. (28)Iron Supplementation150 apparently healthy children <12 yearsIntermittent iron with vitamin C supplements verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.06 (0.00, 0.97)NR
De-Regil et al. (28)Iron Supplementation1107 apparently healthy children <12 yearsIntermittent iron with MMN supplements verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.16 (0.06, 0.44)NR
De-Regil et al. (28)Iron Supplementation2172 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (0 to 3 months duration)RR (M-H, RE, 95% CI) = 1.24 (0.55, 2.77)NR
De-Regil et al. (28)Iron Supplementation4808 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (> 3 months)RR (M-H, RE, 95% CI) = 1.23 (1.03, 1.47)NR
De-Regil et al. (28)Iron Supplementation4507 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (Iron only)RR (M-H, RE, 95% CI) = 1.17 (0.97, 1.42)NR
De-Regil et al. (28)Iron supplements1366 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (with folic acid)RR (M-H, RE, 95% CI) = 1.55 (1.02, 2.36)NR
De-Regil et al. (28)Iron Supplementation1107 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (with MMN)RR (M-H, RE, 95% CI) = 1.31 (0.31, 5.57)NR
De-Regil et al. (28)Iron Supplementation61,166 apparently healthy children between 5 and 12 yearsIntermittent iron supplements verses placebo or no interventionRR (M-H, RE, 95% CI) = 0.54 (0.33, 0.90)NR
De-Regil et al. (28)Iron Supplementation2145 apparently healthy children between 5 and 12 yearsIntermittent iron supplements verses daily iron supplementsRR (M-H, RE, 95% CI) = 0.95 (0.47, 1.91)NR
Mayo-Wilson et al. (22)Zn/Iron supplementation3482 children between 6 months and 12 years of ageZinc with iron supplementation verses zinc aloneRR (95%CI) = 0.78 (0.67–0.92)
P = 0.54
I2 = 0%
NR
Mayo-Wilson et al. (22) (Anemia prevalence)Zn/Iron supplementation134,287 children between 6 months and 12 years of ageOrally administered zinc supplementation verses no zinc supplementationRR (95%CI) = 1.00 (0.95, 1.06)
P = 0.05
I2 = 37%
NR
Athuman et al. (50)Deworming42,237 children between 2 months and 9 years with anemia in malaria endemic areasIntermittent preventive ± antimalarial treatment verses placeboRR (95%CI) = 0.97 (0.88–1.07)
I2 = 29%
Moderate
Sun et al. (45)Dietary interventions6676 Chinese children with iron deficiency anemia inDietary interventions verses controlOR (FE, 95%CI) = 5.03 (3.09, 8.18)
P = 0.85
I2 = 0%
NR
<18 YEARS
Low et al. (20)Iron Supplementation42,169 participants between 12 and 18 yearsDaily oral iron supplements ± other vitamins (folic acid or vitamin C) verses control/placeboRR (M-H, RE, 95%CI) = 0.32 (0.11, 0.93)
P = 0.037
I2 = 97%
NR
Low et al. (24)Iron supplements71,763 children between 3.3 and 15 yearsDaily iron supplements verses placebo/anti-helminthics/Zinc/multivitaminRR (M-H, RE, 95%CI) = 0.50 (0.39–0.64)
P ≤ 0.001
I2 = 85%
NR
De-Regil et al. (31)Fortification3543 children ≥5 yearsPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.53 (0.25, 1.12)
P = 0.097
I2 = 81%
NR
Aaron et al. (32)Fortification62,828 apparently healthy children between 5 and 18 years of ageNon-dairy MMN beverages fortified compared to non-fortified beveragesRR (M-H, RE, 95%CI) = 0.63 (0.54, 0.73)
P < 0.00001
I2 = 84%
Moderate
Neuberger et al. (21)Iron supplementation3633 children in malaria endemic areasIron plus folic acid vs. placebo/no treatmentRR (M-H, RE, 95% CI) = 0.49 (0.25, 0.99), P = 0.14, I2 = 49%NR
Neuberger et al. (21)Iron supplementation153,784 children <18 years in malaria endemic areasIron vs. placebo/no treatmentRR (M-H, RE, 95% CI) = 0.63 (0.49, 0.82), P ≤ 0.00001, I2 = 97%NR
Neuberger et al. (21)Iron supplementation2295 children <18 years in malaria endemic areasIron + antimalarial vs. placeboRR (M-H, RE, 95% CI) = 0.44 (0.28, 0.70), P = 0.20, I2 =40%NR

Findings for anemia in included systematic reviews.

Figure 2

Figure 2

Findings of systematic reviews on anemia.

In infants, iron fortification decreased the risk of anemia by 58% (RR = 0.42, 95%CI = 0.24–0.72; six studies; 1,234 participants; moderate QoE) (34) and MMN fortification by 41% (RR = 0.59, 95%CI = 0.50–0.70; three studies; 1809 participants; low QoE) (34).

In children under 2 years of age, home fortification, when used as a preventive measure, showed maximum reduction in the risk of anemia by 46% (RR = 0·54, 95%CI = 0.46–0.64; 4,331 participants 6M−2Y) (40). However, when used as a treatment measure, it led to an insignificant increase in the risk of anemia by 4% (RR = 1.04, 95%CI = 0.76–1.41; 1,263 participants 6M−2Y) (40). In the same age group, iron supplementation significantly reduced the risk of anemia by 39% (RR = 0·61, 95%CI = 0.50–0.74; I2 = 86%; 17 studies; 4,825 participants 4–23M) (25), followed by home fortification with MMP (compared to placebo/no intervention) by 31% (RR = 0.69, 95%CI = 0.60–0·78; I2 = 19%; six studies; 1,447 participants 4–23M; moderate QoE) (38).

Milk fortification significantly reduced the odds of anemia in healthy children between 6 and 47 months old by 64% (OR = 0.36, 95%CI = 0.14–0.91) (30). Fortification of food with iron and MMN (RR = 0.43, 95%CI = 0.26–0.71; I2 = 80.5%; seven studies, 1,927 participants 6M−5Y) (36) and intermittent iron supplementation (RR = 0.43, 95% CI = 0.23–0.80; four studies; 658 apparently healthy children <5 years) (28) reduced the risk of anemia significantly by 57%, followed by fortification of milk and cereals with iron by 50% (RR = 0.50, 95%CI = 0.33–0.75; I2 = 71.2%; 11 studies; 3,100 participants 6M−5Y) (36), and point-of-use fortification of milk with MMP by 36% (RR = 0.64, 95%CI = 0.44–0.93; I2 = 73%; six studies; 1,706 participants 2–5Y) (31). Single-iron fortification of milk (RR = 0.76, 95%CI = 0.45–1.28; I2 = 0%; four studies; 1,173 participants 6M−5Y) (36), daily doses of FS (RR = 0.73, 95%CI = 0.49–1.09; I2 > 75%; participants aged <5Y) (23), and weekly doses of FS (RR = 0.64, 95%CI = 0.27–1.54; I2 > 75%; participants <5Y) (23) showed insignificant reductions in the risk of anemia by 36, 27, and 24%, respectively.

In preschool and school-age children, MMN fortification showed a maximum reduction in the risk of anemia by 55% (RR = 0.45, 95%CI = 0.22–0.89; five studies; 1,246 participants) (34), followed by iron fortification by 40% (RR = 0.60, 95%CI = 0.43–0.84; 10 studies; 2,013 participants) (34), point-of-use fortification of food with micro nutrient powders (MNP) by 34% (RR = 0.66, 95%CI = 0.49–0.88; I2 = 73%;10 studies; 2,448 participants; moderate QoE) (31), and point-of-use fortification of food with iron, vitamin A, and Zn by 28% (RR0·72, 95%CI = 0.65–0.80; I2 = 0%; seven studies; 1,705 participants with malaria) (31). In children with malaria, point-of-use fortification of food with MNP insignificantly reduced the risk of anemia by 43% (RR = 0.57, 95%CI = 0.29–1.14; I2 = 83%; four studies; 934 participants with malaria) (31).

In apparently healthy children under 12 years of age, maximum reduction in the risk of anemia is seen with intermittent iron and MMN supplementation by 84% (RR = 0.16, 95%CI = 0.06–0.44; one study; 107 participants <12 years) (28), followed by intermittent iron supplementation (iron alone) by 52% (RR = 0.48, 95%CI = 0.31–0.74; six studies; 1,074 participants <12 years). Daily iron/folic acid (FA)/MMN supplementation showed better results as compared with intermittent iron/FA/MMN supplementation (28).

Daily oral iron supplements with or without other vitamins (FA or vitamin C) reduced the risk of anemia in children between 12 and 18 years by 68% (RR = 0.32, 95%CI = 0.11–0.93; I2 = 97%; four studies; 2,169 participants) (20), and in children between 3.3 and 15 years reduced the risk of anemia by 50% (RR = 0.50, 95%CI = 0.39–0.64; I2 = 85%; seven studies; 1,763 participants) (24). Administration of non-dairy, MMN-fortified beverages in children between 5 and 18 years in LMICs effectively reduced the risk of anemia by 37% (RR = 0.63, 95%CI = 0.54–0.73; I2 = 17%; six studies; 2,995 participants) (32). In malaria-endemic areas, additional supplementation of iron along with antimalarial treatment reduced the risk of anemia by 56% (RR = 0.44, 95%CI = 0.28–0.70; I2 = 40%; two studies; 295 participants <18Y), followed by iron and FA supplementation by 51% (RR = 0.49, 95%CI = 0.25–0.99; I2 = 49%; three studies; 633 participants <18Y), and iron supplementation by 37% (RR = 0.63, 95%CI = 0.49–0.82; I2 = 97%; 15 studies; 3,784 participants <18Y) (21).

Hb Levels

Twenty-five reviews addressed the effect of different interventions on Hb levels in children and adolescents (2026, 2831, 3338, 40, 41, 43, 44, 4648, 50) (Table 3 and Figure 3). We did not find any review that assessed the effect of WASH intervention on Hb status.

Table 3

SRInterventionNo of included studiesNumber of participantsComparisonMeta-analysisQuality of evidence
INFANTS
Das et al. (34)MMN fortification71,508 infantsMMN fortification verses unfortified foods/regular dietSMD (95% CI) = 1.05 (0.48, 1.63)Moderate
Das et al. (34)Iron fortification121,834 infantsIron fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.81 (0.31, 1.31)Moderate
Gera et al. (37)Iron fortification9InfantsIron fortification verses non-fortified foodWMD (95%CI) = 0.5 (0.28, 0.72) g/dL
P ≤ 0.001
I2 = 74.7%
NR
Salam et al. (35)MNP supplementation/fortification148,354 children between 2 months and 1 year of age from developing countriesMNP vs. no intervention or controlSMD (IV, RE,95%CI) = 0.98 (0.55, 1.40)
P < 0.00001
I2 = 99%
Moderate
Das et al. (33)Zinc fortification392 children (malnourished, preterm infants, or <9 years of age)Zinc fortification verses controlSMD (FE, 95%CI) = −0.11(−0.52, 0.31)
P = 0.45
I2 = 0%
NR
CHILDREN <2 YEARS OF AGE
Pasricha et al. (25)Iron supplementation265,479 children between 4 months and 2 years of ageIron supplementation verses controlMD (95%CI) = 7.22 (4.87–9.57) g/L
P < 0.0001
I2 = 94%
NR
De-Regil et al. (38)Home fortification61,447 children between 6 and 23 monthsHome fortification with MMP verses placebo/no interventionMD (IV, RE, 95%CI) = 5.87 (3.25–8.49) g/LModerate
Dewey et al. (40)Home fortification222,449 between children 6 months and 2 years of ageHome fortification as prevention verses control5.06 (2.29, 7.83) g/LNR
Gera et al. (44) (change in Hb)Iron supplementation/ fortification29Children ≤ 2 years of ageIron supplementation/ fortification verses controlWMD (RE, 95%CI) = 0.56 (0.36, 0.76) g/dL
P < 0.001
NR
Gera et al. (37)Iron fortification45Children >1 year of ageIron fortification verses non-fortified foodWMD (RE, 95%CI) = 0.49 (0.31, 0.67) g/dL
P < 0.001 I2 = 94%
NR
Dewey et al. (40)Home fortification-1,263 children between 6 months and 2 years of ageHome fortification as treatment verses iron drops−0.91 (−11.96, 10.14) g/LNR
De-Regil et al. (38)Home fortification2278 children 6–23 monthsHome fortification with MMP verses iron supplementsMD (IV, RE, 95%CI) = −2.36 (−10.30 to 5.59) g/L
I2 = 78%
Low
<5 YEARS
Thompson et al. (26) (end point)Iron supplementation91,690 children between 2 and 5 years of ageDaily iron supplementation ≥5 days/week verses controlMD (95% CI) = 6.97 (4.21, 9.72) g/L
P < 0.00001
I2 = 82%
High
De-Regil et al. (28)Iron supplementation91,254 apparently healthy children <5 years of ageIntermittent iron supplements verses placeboMD (IV, RE, 95%CI) = 6.45 (2.36, 10.55) g/LNR
Eichler et al. (36)Iron + MMN fortification81,803 Infants and children from 6 months to 5 years of ageIron + MMN fortification verses non-fortified foodMD (95% CI) = 0.87 (0.57–1.16) g/dL
P = 0.00
I2 = 81.5%
NR
Eichler et al. (36)Iron fortification132,274 Infants and children from 6 months to 5 years of ageIron fortification of milk and cereals verses non-fortified foodMD (95% CI) = 0.62 (0.34, 0.89) g/dL
P = 0.00
I2 = 86.2%
NR
Gera et al. (44) (change in Hb)Iron supplementation/ fortification44Children ≤ 5 years of ageIron supplementation/ fortification verses controlWMD (RE, 95%CI) = 0.59 (0.43, 0.75)g/dL
P < 0.001
NR
Cembranel et al. (23)Iron supplementation14Children <5 years of ageDaily doses of FS verses controlMD (95%CI) = 0.56 (0.31, 0.81) mg/dL
P < 0.001
NR
Kristjansson et al. (41) [change in Hb (g/L)]Supplementary feeding5300 children aged 3 months to 5 years in LMICsSupplementary feeding verses controlSMD (IV,RE, 95%CI) = 0.49 (0.07–0.91) g/L
I2 = 63%
NR
Matsuyama et al. (30)Milk fortificationNRHealthy children aged 6–47 monthsFortified milk verses controlMD (95%CI) = 5·89 (−0·24, 12·02) g/L
P = 0.06
NR
De-Regil et al. (31) (g/L)MNP fortification72,023 children between 2 and 5 years of agePoint-of-use fortification of foods with MNP verses no intervention or placeboMD (IV, RE, 95%CI) = 2.02 (−0.87, 4.92) g/LNR
Eichler et al. (36)Iron fortification5471 Infants and children from 6 months to 5 years of ageIron single-fortification verses non-fortified foodMD (95% CI) = 0.20 (−0.05–0.45) g/dL
P = 0.132
I2 = 43.4%
NR
Cembranel et al. (23)Iron supplementation07Children <5 years of ageWeekly doses of FS verses controlMD (95%CI) = 0.28 (−0.22, 0.78) mg/dL
P = 0.273
NR
Cembranel et al. (23)Iron supplementation03Children <5 years of ageDaily doses verses control weekly doses of FSMD (95%CI) = 0.28 (−0.01, 0.56) mg/dL
P = 0.057
NR
De-Regil et al. (28)Iron supplementation142,270 apparently healthy children <5 years of ageIntermittent iron supplements verses daily iron supplementsMD (IV, RE, 95%CI) = −0.75 (−1.80, 0.29) g/LNR
CHILDREN <12 YEARS
De-Regil et al. (31)MNP Fortification112,746 preschool and school-age childrenPoint-of-use fortification of foods with MNP verses no intervention or placeboMD (95%CI) = 3.37 (0.94, 5.80) g/LLow
Das et al. (34)Iron fortification163,832 preschool and school-going childrenIron fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.46 (0.14, 0.50)Moderate
Das et al. (34)MMN fortification71,543 preschool and school-going childrenMMN fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.45 (0.12, 0.79)Moderate
Mayo-Wilson et al. (22)Zn supplementation276,024 Children between 6 months and 12 years of ageZinc supplementation verses no zinc supplementationSMD (95%CI) = −0.05 (−0.10,0.00)
P = 0.002
I2 = 45%
Low
Mayo-Wilson et al. (22)Zn + Iron supplementation81,341 Children between 6 months and 12 years of ageZinc with iron supplementation verses zinc aloneSMD (95%CI) = −0.23 (−0.34,−0.12)
P < 0.0001
I2 = 79%
Low
De-Regil et al. (28)Iron supplementation193,032 apparently healthy children <12 yearsIntermittent iron supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = 5.20 (2.51,7.88) g/L
P = 0.00015
I2 = 93%
Low
De-Regil et al. (28)Iron supplementation71,616 apparently healthy children <12 yearsIntermittent iron supplementation (0–3 months duration) verses placebo/no interventionMD (IV, RE, 95%CI) = 5.16 (0.90, 9.36) g/LNR
De-Regil et al. (28)Iron supplementation121,416 apparently healthy children <12 yearsIntermittent iron supplementation (>3 months duration) verses placebo/no interventionMD (IV, RE, 95%CI) = 5.13 (2.82, 7.51) g/LNR
De-Regil et al. (28)Iron supplementation111,699 apparently healthy children <12 yearsIntermittent iron only supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = 4.41 (1.32, 7.50) g/LNR
De-Regil et al. (28)Iron supplementation4756 apparently healthy children <12 yearsIntermittent iron folic acid supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = 3.36 (1.51, 5.21) g/LNR
De-Regil et al. (28)Iron +Zinc supplementation177 apparently healthy children <12 yearsIntermittent iron with zinc supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = −1.60 (−8.09, 4.89) g/LNR
De-Regil et al. (28)Iron +Vit C supplementation150 apparently healthy children <12 yearsIntermittent iron with vitamin C supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = 20.70 (17.51, 23.89) g/LNR
De-Regil et al. (28)Iron +MMN supplementation4450 apparently healthy children <12 yearsIntermittent iron with MMN supplementation verses placebo/no interventionMD (IV, RE, 95%CI) = 5.47 (0.32, 10.61) g/LNR
De-Regil et al. (28)Iron ± MMN supplementation192,851 apparently healthy children <12 yearsIntermittent iron supplements ± MMN verses daily iron supplements ± MMNMD (IV, RE, 95%CI) = −0.60(−1.54,0.35) g/L
P = 0.22
I2 = 56%
Low
De-Regil et al. (28)Iron supplementation111,455 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (0–3 months duration)MD (IV, RE, 95%CI) = 0.47 (−0.91, 1.84) g/LNR
De-Regil et al. (28)Iron supplementation81,387 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (> 3 months duration)MD (IV, RE, 95%CI) = −1.14 (−2.07,−0.22) g/LNR
De-Regil et al. (28)Iron supplementation152,144 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (Iron alone)MD (IV, RE, 95%CI) = −0.51 (−1.61, 0.59) g/LNR
De-Regil et al. (28)Iron supplementation2408 apparently healthy children <12 yearsIntermittent iron supplements verses daily iron supplements (With folic acid)MD (IV, RE, 95%CI) = −2.26 (−4.30,−0.22) g/LNR
De-Regil et al. (28)Iron supplementation3299 apparently healthy children <12 years of ageIntermittent iron supplements verses daily iron supplements (With MMN)MD (IV, RE, 95%CI) = 0.61 (−2.04, 3.26) g/LNR
De-Regil et al. (28)Iron supplementation101,778 apparently healthy children between 5 and12 years of ageIntermittent iron supplements verses placebo or no interventionMD (IV, RE, 95%CI) = 4.04 (0.30, 7.78) g/LNR
De-Regil et al. (28)Iron supplementation5581 apparently healthy children between 5 and 12 years of ageIntermittent iron supplements verses daily iron supplementsMD (IV, RE, 95%CI) = −0.31 (−2.59, 1.97) g/LNR
CHILDREN <18 YEARS OF AGE
Girum et al. (47) (change in Hb)Deworming810,05,239 school children from Asia and AfricaDeworming verses controlWMD (FE, 95%CI) = 1.62 (1.01–2.25) g/dL
P = 0.873
I2 = 0%
NR
Low et al. (24)Iron supplementation286,545 primary-school–aged children between 3.3 and 15 yearsIron supplementation verses placebo/anti-helminthic therapy/Zinc/multi-vitaminMD (95%CI) = 8.38 (6.21–10.56) g/L
P < 0.001
I2 = 97%
NR
Low et al. (20) (end of treatment)Iron supplementation103,220 participants between 12 and 18yearsDaily oral iron supplementation with or without other vitamins (folic acid or vitamin C)/verses control/placeboMD (IV, RE, 95%CI) = 6.99 (3.85, 10.13) g/L
P = 0.00001
I2 = 95%
NR for subgroup
Aaron et al. (32)MMN fortification83,835 apparently healthy children between 5 and 18 years of ageMMN fortified beverages verses non-fortified beverages2.79 (1.19, 4.33) g/L
P = 0.004
I2 = 92%
Moderate
Ramakrishnan et al. (29)Iron interventions162,542 children between 6 months and 18 yearsIron interventions verses controlWMD (95%CI) = 1.49 (0.46, 2.51)NR
Gera et al. (44) (change in Hb)Iron supplementation/fortification9112,198 children <18 years of ageIron supplementation/ fortification verses controlWMD (95%CI) = 0.74 (0.61–0.87) g/dL
P < 0.001
NR
Gera et al. (44) (change in Hb)Iron supplementation82Children <18 years of ageIron supplementation verses controlWMD (95%CI) = 0.79 (0.65, 0.94) g/dL
P < 0.001
NR
Gera et al. (44) (change in Hb)Iron fortification9Children <18 years of ageIron fortification verses controlWMD (RE, 95%CI) = 0.25 (0.02, 0.52) g/dL
P = 0.065
NR
Gera et al. (44) (change in Hb)Iron supplementation/ fortification47Children >5 years of ageIron supplementation/ fortification verses controlWMD (RE, 95%CI) = 0.88 (0.67, 1.08) g/dL
P < 0.001
NR
Gera et al. (44) (change in Hb)Iron supplementation/fortification13Children <18 years of age from developed countriesIron supplementation/ fortification verses controlWMD (RE, 95%CI) = 0.46 (0.13, 0.78) g/dL
P = 0.007
NR
Gera et al. (44) (change in Hb)Iron supplementation/ fortification78Children <18 years of age from developing countriesIron supplementation/ fortification verses controlWMD (RE, 95%CI) = 0.78 (0.64, 0.93) g/dL
P < 0.001
NR
Das et al. (34)Vitamin A fortification21,538 children <18 years of ageVitamin A fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.48 (0.07, 0.89)Low
Das et al. (34)Iron fortification204,176 children from UMHICsIron fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.67 (0.36, 0.97)Moderate
Das et al. (34)MMN fortification81,769 children from LMICsMMN fortification verses unfortified foods/ regular dietSMD (95% CI) = 0.50 (0.21, 0.78)Moderate
Das et al. (34)MMN fortification61,282 children from UMHICsMMN fortification verses unfortified foods/ regular dietSMD (95% CI) = 1.25 (0.45, 2.06)Moderate
Das et al. (34)Zinc fortificationNRChildren below 18 yearsZinc fortification verses unfortified foods/ regular dietSMD (95% CI) = −0.11 (−0.52, 0.31)Low
Gera et al. (43) (change in Hb)Iron and MMN supplementation254,981 children <15 years from developing countriesIron and MMN supplementation verses placeboWMD (RE, 95 % CI) = 0.65 (0.50, 0.80) g/L
P < 0.001
I2 = 89.6 %
NR
Gera et al. (43) (change in Hb)Iron and MMN supplementation131,483 children <15 years from developing countriesIron and MMN supplementation verses iron supplementation aloneWMD (95 % CI) = 0.14 (0.00, 0.28) g/L
P = 0.044
I2 = 76.0%
NR
Gera et al. (43)Iron and micronutrient supplementation18Children <15 years from developing countriesIron and micronutrient supplementation verses placeboWMD (RE, 95%CI) = 0.69 (0.48, 0.91) g/L
P < 0.001
NR
Gera et al. (43)Iron and micronutrient fortification15Children <15 years from developing countriesIron and micronutrient fortification verses placeboWMD (RE, 95%CI) = 0.61 (0.40, 0.81) g/L
P < 0.001
NR
Gera et al. (43)Iron and micronutrient supplementation9Children <15 years from developing countriesIron and micronutrient supplementation verses ironWMD (95 % CI) = 0.27 (0.13, 0.41) g/L
P < 0.001
I2 = 8.5%
NR
Gera et al. (43)Iron and micronutrient fortification6Children <15 years from developing countriesIron and micronutrient fortification verses ironWMD (95 % CI) = 0.06 (20.15, 0.27) g/L
P = 0.55
I2 = 89.3%
NR
De-Regil et al. (31)MNP Fortification3524 children aged ≥5 yearsPoint-of-use fortification of foods with MNP verses no intervention or placeboMD (IV, RE, 95%CI) = 7.86 (−0.76, 16.49) g/LNR
Neuberger et al. (21) (end of treatment)Iron supplementation165,261Children <18 years of age from malaria endemic areasIron vs. placebo or no treatmentMD (IV, RE, 95%CI) = 0.75 (0.48, 1.01) g/dL
P < 0.00001
I2 = 93%
NR
Neuberger et al. (21) (change in Hb)Iron supplementation122,462 children <18 years of age from malaria endemic areasIron vs. placebo or no treatmentMD (IV, RE, 95%CI) = 0.67 (0.42, 0.92) g/dL
P < 0.00001
I2 = 82%
NR
Neuberger et al. (21) (end of treatment)Iron plus folic acid supplementation1124 children <18 years of age from malaria endemic areasIron plus folic acid vs. placeboMD (IV, RE, 95%CI) = 0.90 (0.51, 1.29) g/dL
P < 0.00001
I2 = NA
NR
Neuberger et al. (21) (end of treatment)Iron plus anti-malarial treatment1151 children <18 years of age from malaria endemic areasIron plus anti-malarial treatment vs. placeboMD (IV, RE, 95%CI) = 0.91 (0.47, 1.35) g/dL
I2 = NA
NR
Athuman et al. (50) (mean change in Hb)Anti-malarial treatment41,672 children with anemia in Malaria-endemic areasIntermittent preventive antimalarial treatment verses placebo (IPT ± iron and folic acid verses placebo ± iron and folic acid)MD (IV, FE) = 0.32 (0.19, 0.45) g/dL
I2 = 18%
Low
Athuman et al. (50) (mean Hb)Anti-malarial treatment41,672 children with anemia in Malaria-endemic areasIntermittent preventive antimalarial treatment verses placebo (IPT ± iron and folic acid verses placebo ± iron and folic acid)MD (IV, FE) = 0.35 (0.06, 0.64) g/dL
I2 = 76%
Low
Taylor-Robinson et al. (46)Deworming41,992 children <16 years in areas endemic for intestinal helminthesDeworming drugs verses no interventionMD (IV,FE, 95%CI) = 0.02 (−0.05, 0.09) g/dL
P > 0.05
Low
Taylor-Robinson et al. (46)Deworming2108 children <16 years in areas endemic for intestinal helminthes or children screened for infectionSingle dose deworming drugs verses no interventionMD (IV,FE, 95%CI) = 0.37 (0.10, 0.64) g/dL
P = 0.008
I2 = 0%
Low
Taylor-Robinson et al. (46)Deworming2658 children <16 years in areas endemic for intestinal helminthes (moderate prevalence)Single dose deworming drugs (targeted intervention) verses no interventionMD (IV,FE, 95%CI) = 0.06 (−0.06, 0.17) g/dL
P = 0.34
I2 = 0%
NR
Taylor-Robinson et al. (46)Deworming21,334 children <16 years in areas endemic for intestinal helminthes (low prevalence)Single dose deworming drugs (targeted intervention) verses no interventionMD (IV,FE, 95%CI) = 0.00 (−0.08, 0.08) g/dL
P = 0.92
I2 = 0%
NR
Taylor-Robinson et al. (46) (in first year)Deworming4807 children <16 years in areas endemic for intestinal helminthesMultiple dose deworming drugs verses no interventionMD (IV,FE, 95%CI) = 0.01 (0.13, 0.14) g/dLLow
Taylor-Robinson et al. (46) (in first year)Deworming2464 children <16 years in areas endemic for intestinal helminthes (moderate prevalence)Multiple dose deworming drugs (targeted intervention) verses no interventionMD (IV,FE, 95%CI) = 0.02 (−0.15, 0.19) g/dL
P = 0.82
I2 = 0%
NR
Taylor-Robinson et al. (46) (in first year)Deworming2343 children <16 years in areas endemic for intestinal helminthes (low prevalence)Multiple dose deworming drugs (targeted intervention) verses no interventionMD (IV,FE, 95%CI) = −0.06 (−0.28, 0.17) g/dL
P = 0.62
I2 = 0%
NR
Taylor-Robinson et al. (46) (after first year)Deworming21,365 children <16 years in areas endemic for intestinal helminthes (low prevalence)Multiple dose deworming drugs (targeted intervention) verses no interventionMD (IV,FE, 95%CI) = −0.02 (−0.30, 0.27) g/dL
P = 0.91
I2 = 0%
Very low
Huang et al. (48) (changes in Hb)H. pylori treatment4<18 years of ageH. pylori treatment for eradication verses placeboWMD (IV, RE, 95%CI) = 11.77 (2.40, 21.15) g/L
P = 0.01
I2 = 90%
NR

Findings for hemoglobin in included systematic reviews.

Figure 3

Figure 3

Findings of SRs on Hb.

In infants, MMN fortification showed maximum improvement in Hb (SMD = 1.05, 95%CI = 0.48–1.63; seven studies; 1,508 participants; moderate QoE) (34), followed by iron fortification (SMD = 0·81, 95%CI = 0.31–1.31; 12 studies; 1,834 infants; moderate QoE) (34).

In children under 2 years old, daily iron supplementation showed significant improvements in Hb (MD = 7.22 g/L, 95%CI = 4.87–9.57; I2 = 94%; 26 studies; 5,479 participants 4M−2Y) (25), followed by MMN fortification (MD = 5.87 g/L, 95%CI = 3.25–8.49, six studies, 1,447 participants 6M−2Y) (38), and home fortification (5.06 g/L; 95%CI = 2.29–7.83, 22 studies, 2,449 participants 6M−2Y) (40). Home fortification did not show a significant impact on Hb levels as compared with iron drops (−0.91 g/L; 95%CI = −11.96–10.14; 1,263 participants 6M−2Y) (40) or iron supplements (MD = −2.36 g/L; 95%CI = −10.30–5.598, I2 = 78%, two studies, 278 participants 6M−2Y) (38).

In children under 5 years old, maximum improvement in Hb levels was seen with MMN fortification (MD = 0.87 g/dL, 95%CI = 0.57–1.16; I2 = 82%; eight studies; 1,803 participants 6M−5Y) (36), followed by daily iron supplementation (MD = 6.97 g/L, 95%CI = 4.21–9.72; I2 = 82%; nine studies; 1,690 participants 2–5Y; high QoE) (26), intermittent iron supplementation (MD = 6.45 g/L, 95%CI = 2.36–10.55; nine studies, 1,254 apparently healthy participants <5Y) (28), iron fortification of milk and cereals (MD = 0.62 g/dL, 95%CI = 0.34–0.89; I2 = 86.2%; 13 studies, 2,274 participants 6M−5Y) (36), and daily FS supplementation (MD = 0.56 mg/dL, 95%CI = 0.31–0.81; 14 studies; participants <5Y) (23). Insignificant changes were observed with fortified milk (MD = 5.89 g/L, 95%CI = −0.24–12.02) (30), point-of-use fortification of food with MNP (MD = 2.02 g/L, 95%CI = −0.87 to 4.92) (31), single iron fortification (MD = 0.20 g/dL, 95%CI = −0.05 to 0.45) (36), and weekly FS supplementation (MD = 0.28 mg/dL; 95%CI = −0.22 to 0.78) (23).

The maximum effect on Hb in preschool and school-age children was seen with iron fortification (SMD = 0.46, 95%CI = 0.24–0.67; 16 studies; 3,832 participants; moderate QoE) (34) and MMN fortification (SMD = 0.45, 95%CI = 0.12–0.79; seven studies; 1,543 participants; moderate QoE) (34) followed by point-of-use fortification with MMN (MD = 3.37 g/L, 95%CI = 0.94–5.80; 11 studies; 2,746 participants; low QoE) (31). In apparently healthy children under 12 years of age, intermittent supplementation with iron alone or in combination with other nutrients effectively increased Hb concentrations, and this positive response did not differ between frequency or duration of supplementation or age of children (28).

In children under 15 years of age, daily iron supplementation (MD = 8.38 g/L, 95%CI = 6.21–10.56; I2 = 97%; 28 studies; 6,545 participants 3.3–15Y) (24) and iron with micronutrient supplementation (WMD = 0.69 g/L, 95%CI = 0.48–0.91; 18 studies; participants <15Y) showed better improvements in Hb than iron with micronutrient fortification (WMD = 0.61 g/L, 95%CI = 0.40–0.81; 15 studies; participants <15Y) (43). A school-based deworming program resulted in a decreased prevalence of anemia (WMD = 1.62, 95%CI = 1.01–2.25; I2 = 0%; eight studies; 1,005,239 participants) (47).

In children under 18 years of age, point-of-use fortification of food with MMP showed maximum though insignificant improvements in Hb levels (MD = 7.86 g/L, 95%CI = −0.76–16.49; three studies; 524 participants ≥5Y) (31). Daily oral iron supplementation with or without other vitamins (MD = 6.99 g/L, 95%CI = 3.85–10.13; I2 = 95%; 10 studies; 3,220 participants 12–18Y) (20) and MMN-fortified beverages (2.76 g/L, 95%CI = 1.19–4.33; eight studies; 3,855 apparently healthy participants 5–18Y) showed significant improvements (32). Also, there was a substantially higher increase in Hb concentration from iron interventions (WMD = 1.49, 95%CI = 0.46–2.51; 16 studies; 2,542 participants 6M−18Y) (29) than oral iron supplementation (WMD = 0.79 g/dL, 95%CI = 0.65–0.94; 82 studies) and iron fortification (WMD = 0.25 g/dL, 95%CI = 0.02–0.52; nine studies; participants <18Y) (44). Fortification of food with vitamin A substantially increased Hb concentrations in children under 18 years of age (SMD = 0.48, 95%CI = 0.07 = 0.89; two studies; 1,538 participants <18Y), with iron (SMD = 0.67, 95%CI = 0.36–0.97; 20 studies; 4,176 participants <18Y from UMHICs), and with MMN (SMD = 0.50, 95%CI = 0.21–0.78; eight studies; 1,769 participants <18Y from LMICs) (34).

In children under 18 years of age residing in malaria-endemic areas, iron with antimalarial treatment (MD = 0.91 g/dL, 95%CI = 0.47–1.35; one study; 151 participants <18Y) and iron with FA supplementation (MD = 0.90 g/dL, 95%CI = 0.51–1.29; one study; 124 participants <18Y) showed better results as compared with iron-only supplementation (MD = 0.75 g/dL, 95%CI = 0.48–1.01; I2 = 93%; 16 studies; 5,261 participants <18Y) (21). There is low-quality evidence that community deworming has little or no effect (MD = 0.02 g/dL, 95%CI = −0.05 to 0.09; I2 = 0%; two studies; 464 participants <16Y) and that, in programs that treat only infected children, a single dose of deworming may improve Hb (MD = 0.37 g/dL, 95%CI = 0.10–0.64; two trials; 108 participants <16Y; low QoE) (46). Additional H. pylori eradication therapy along with iron administration provided better improvements in iron deficiency anemia than iron administration alone (WMD = 11.77 g/L, 95%CI = 2.40–21.15; I2 = 90%; four studies; participants <18Y) (48).

Adverse Events

A total of six reviews addressed the adverse effects of different interventions for preventing, treating, and controlling anemia (21, 22, 24, 25, 28, 31) (Table 4). We did not find any review that assessed the adverse effects of antimalarial intervention, deworming, H. pylori treatment, or WASH interventions.

Table 4

SR#Included studies#ParticipantsComparisonMeta-analysisQuality of evidence
CHILDREN <2 YEARS
Pasricha et al. (25) (vomiting)Iron supplements31,020 children between 4 and 23 monthsIron supplementation verses controlRR (95%CI) = 1.38 (1.10–1.73)
P = 0.006
I2 = 1%
NR
Pasricha et al. (25) (diarrhea prevalence)Iron supplements61,697 children between 4 and 23 monthsIron supplementation verses controlRR (95%CI) = 1.03 (0.86–1.23)
P = 0.78
I2 = 0%
NR
Pasricha et al. (25) (constipation)Iron supplements2570 children between 4 and 23 monthsIron supplementation verses controlRR (95%CI) = 0.54 (0.05–5.83)
P = 0.49
I2 = 77%
NR
Pasricha et al. (25) (any adverse events)Iron supplements3912 children between 4 and 23 monthsIron supplementation verses controlRR (95%CI) = 1.10 (0.98–1.25)
P = 0.12
I2 = 0%
NR
CHILDREN <12 YEARS
De-Regil et al. (28)Iron supplements153 apparently healthy children <5 years of ageIntermittent supplementation verses placebo or no interventionRR (M-H, RE, 95%CI) = 3.87 (0.19, 76.92)NR
De-Regil et al. (28)Iron supplements4895 apparently healthy children <5 years of ageIntermittent iron supplements verses daily iron supplementsRR (M-H, RE, 95%CI) = 0.60 (0.19, 1.87)NR
De-Regil et al. (28)Iron supplements153 apparently healthy children between 5 and 12 years of ageIntermittent supplementation verses placebo or no interventionRR (M-H, RE, 95%CI) = 3.87 (0.19, 76.92)NR
De-Regil et al. (28) (any AE)Iron supplements153 apparently healthy children <12 yearsIntermittent supplementation with iron alone or with other nutrients verses placebo or no interventionRR (M-H, FE, 95%CI)= 3.87 (0.19, 76.92)
P = 0.37
I2 =NA
NR
De-Regil et al. (28) (nausea)Iron supplements164 apparently healthy children <12 yearsIntermittent supplementation with iron alone or with other nutrients verses placebo or no interventionRR (M-H, RE, 95%CI)
2.82 (0.12, 66.82)
P = 0.52
I2 =NA
NR
De-Regil et al. (28) (any AE)Iron supplements4895 apparently healthy children <12 yearsIntermittent iron supplements ± other micronutrients verses daily iron supplements ± other micronutrientsRR (M-H, RE, 95%CI)= 0.60 (0.19, 1.87)
P = 0.38
I2 = 87%
NR
De-Regil et al. (28) (diarrhea)Iron supplements1122 apparently healthy children <12 yearsIntermittent iron supplements ± other micronutrients verses daily iron supplements ± other micronutrientsRR (M-H, RE, 95%CI)= 1.17 (0.60, 2.28)
P = 0.65
I2 =NA
NR
Mayo-Wilson et al. (22) (incidence of vomiting)Zn/Iron supplementation54,095 Children between 6 months and 12 years of ageZinc supplementation verses no zinc supplementationRR (95%CI) = 1.68 (1.61, 1.75)
P < 0.00001
I2 = 85%
Low
Mayo-Wilson et al. (22) (prevalence of vomiting)Zn/Iron supplementation435,192 Children between 6 months and 12 years of ageZinc supplementation verses no zinc supplementationRR (95%CI) = 1.29 (1.14, 1.46)
P = 0.18
I2 = 37%
Low
Mayo-Wilson et al. (22) (study withdrawal)Zn/Iron supplementation64,263 Children between 6 months and 12 years of ageZinc supplementation verses no zinc supplementationRR (95%CI) = 1.75 (0.93, 3.32)
P = 0.28
I2 = 21%
Low
Mayo-Wilson et al. (22) (study withdrawal)Zn/Iron supplementation2557 Children between 6 months and 12 years of ageZinc with iron supplementation verses zinc alone supplementationRR (95%CI) = 1.41 (0.91, 2.18)
P = 0.78
I2 = 0%
Low
De-Regil et al. (31) (adverse effects)Food fortification190 Preschool and school-age childrenPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 1.09 (0.16–7.42)
P > 0.05
I2 =NA
Moderate
De-Regil et al. (31) (diarrhea)Food fortification2366 Preschool and school-age childrenPoint-of-use fortification of foods with MNP verses no intervention or placeboRR (M-H, RE, 95%CI) = 0.97 (0.53, 1.78)
P = 0.93
I2 = 0%
Low
Low et al. (24) (gastrointestinal upset)Iron supplementation4576 primary-school–aged children between 3.3 and 15 yearsIron supplementation verses placebo/antihelminthic therapy/Zinc/multi-vitaminRR (95%CI) = 1.30 (0.89–1.91)
P = 0.2
I2 = 0%
NR
Low et al. (24) (constipation)Iron supplementation2202 primary-school–aged children between 3.3 and 15 yearsIron supplementation verses placebo/antihelminthic therapy/Zinc/multi-vitaminRR (95%CI) = 3.44 (0.66–19.68)
P = 0.2
I2 = 6%
NR
Low et al. (24) (vomiting)Iron supplementation2202 primary-school–aged children between 3.3 and 15 yearsIron supplementation verses placebo/antihelminthic therapy/Zinc/multi-vitaminRR (95%CI) = 0.86 (0.13–5.67)
P = 0.9
I2 = 0%
NR
Neuberger et al. (21) (diarrheal episodes per patient-month by Zn supplements)Iron supplementation823,912 children in malaria endemic areasIron vs. placebo or no treatmentRR (IV, FE, 95%CI) = 1.15 (1.06, 1.26)
P = 0.0014
I2 = 40%
NR
Dewey et al. (40) (diarrhea)Food Fortification8808 children between 5.5 and 18 yearsTreatment home fortification verses control−0.34 (−0.78, 0.03)
P = 0.02
NR
Dewey et al. (40) (diarrhea)Food Fortification101,195 children between 5.5 and 18 yearsPreventive home fortification verses controlRR (95%CI) = 1.07 (0.78, 1.47)
P = 0.72
NR
Neuberger et al. (21) (diarrheal episodes per patient-month without Zn)Iron supplementation717,566 children in malaria endemic areasIron vs. placebo or no treatmentRR (FE, 95%CI) = 0.99 (0.87, 1.13)
P = 0.93
I2 = 0%
NR
Neuberger et al. (21) (diarrheal episodes per patient-month with Zn)Iron supplementation36,346 children in malaria endemic areasIron vs. placebo or no treatmentRR (IV, FE, 95%CI) = 1.29 (1.15, 1.44)
P = 0.000017
I2 = 30%
NR

Findings for adverse events of different interventions for addressing childhood anemias in included systematic reviews.

In children between 4 months and 2 years, there is an uncertain effect of risk of adverse events with iron supplements as compared with controls with a 10% increase in the risk of any adverse event (RR = 1.10, 95%CI = 0.98–1.25; I2 = 0%; three studies, 912 participants), 38% increase in the risk of vomiting (RR = 1.38, 95%CI = 1.10–1.73; I2 = 1%; three studies, 1,020 participants), and 3% increase in the risk of diarrhea (RR = 1.03, 95%CI = 0.86–1.23; I2 = 0%; six studies; 1,697 participants) (25).

In apparently healthy children under 12 years of age, intermittent supplementation of iron alone or with other nutrients showed a 3.87-times risk of any adverse events (RR = 3.87, 95%CI = 0.19–76.92; one study; 53 participants) (28). However, the risk of any adverse events was 40% less (RR = 0.60, 95%CI = 0.19–1.87; I2 = 87%; four studies; 895 participants), and the risk of diarrhea was 1.17 times higher (RR = 1.17, 95%CI = 0.60–2.28; I2 = 0%; one study; 122 participants) with intermittent iron supplements with or without other micronutrients as compared with daily iron supplements with or without other micronutrients (28). There is an insignificant effect of food fortification on adverse effects (RR = 1.09, 95%CI = 0.16–7.42; one study; 90 participants; moderate QoE) and diarrhea (low QoE) in preschool and school-age children (31). The risk of gastrointestinal upset was 1.3 times higher (RR = 1.30, 95%CI = 0.89–1.91; I2 = 0%; four studies; 576 participants), constipation was 3.44 times higher (RR = 3.44, 95%CI = 0.66–19.68; I2 = 6%; two studies, 202 participants), and vomiting was 14% lower (RR = 0.86, 95%CI = 0.13–5.67; I2 = 0%; two studies; 202 participants) with iron supplements in school-aged children between 3.3 and 15 years (24).

In children under 18 years old residing in malaria endemic areas, there is a significantly higher risk of diarrheal episodes per patient-month by 15% with iron supplements (RR = 1.15, 95%CI = 1.06–1.26; eight studies; 23,912 participants) and by 29% with Zn supplements (RR = 1.29, 95%CI = 1.15–1.44; I2 = 30%; three studies, 6,346 participants) (21).

Discussion

We evaluated 31 SRs that assessed the effects of different interventions for addressing anemia in children and adolescents. The highest number of SRs addressed food fortification and iron supplementation. None of the reviews were from India or included participants from India. Overall, the quality of the evidence reported by the SRs varied between moderate to low (Supplementary File 2).

In infants, iron fortification showed better results as compared with MMN fortification (30, 34). In children between 4 months and 2 years of age; home fortification, when used as a preventive measure, showed significant reduction in the risk of anemia followed by iron supplementation (25, 38, 40). However, when used as a treatment measure, home fortification insignificantly increased the risk of anemia (40). This difference in the effect of home fortification when used as a preventive measure and as a treatment measure might be because the prevention trials were conducted on unselected populations, and the participants in the control group did not receive any treatment. On the contrary, the therapeutic trials were conducted on anemic subjects, and the participants in the control received medicinal iron drops (40).

In children under 5 years old and in school-age children, fortification of food with iron and MMN showed better improvement in Hb (moderate QoE) (34, 36). In apparently healthy children under 12 years old, intermittent supplementation of iron alone or in combination with other nutrients significantly increased Hb concentrations, and this positive response did not differ with frequency or duration of supplementation or age of children (28). The risk of anemia is higher with intermittent iron/FA/MMN supplementation as compared with daily iron/FA/MMN supplementation (28). A school-based deworming program resulted in a decrease in the prevalence of anemia in children (47). Programs that combined interventions, such as deworming with iron and nutrition supplementation, led to better effects as compared with single interventions (47). Daily oral iron supplementation with or without other vitamins (20, 24) and MMN-fortified beverages (32) showed maximum reduction in the risk of anemia in children between 3.5 and 18 years. In malaria endemic areas, iron supplementation with antimalarial treatment reduced the risk of anemia (21). There is low-quality evidence that community deworming has little or no effect (46).

In summary, results were favorable for iron with MMN fortification until school age and iron with MMN supplementation in older children with a clear reduction in the risk of anemia and increase in Hb among the intervention groups of individual SRs. However, other interventions reported by SRs were inconclusive and all SRs suggested further research on the same.

The chances of developing anemia were less in children who received daily supplements as compared with those who received intermittent supplements. However, studies suggest that, in places and settings in which daily supplementation is not practical, intermittent supplementation can be used as a public health intervention to address childhood anemia. We did not find any review that assessed the effect of treatment of deworming, H. pylori infection, or WASH intervention on anemia status.

Limitations of the review: This overview examined the available evidence with respect to interventions addressing childhood and adolescent anemia without any restrictions on the type of interventions or language of publication. We did not restrict the search to Cochrane reviews, and inclusion of non-Cochrane reviews makes it more comprehensive. However, wide physiological variations during different stages of childhood could make the uniform application of interventions difficult. We acknowledge that not all SRs included in this overview were up to date. We found limited reviews on deworming, antimalarial interventions, H. pylori intervention, and WASH intervention, and hence, there is a need for primary studies in these areas. Some SRs did not consider socio-economic or nutritional status at baseline or did not report this clearly, which could have had an influence on some findings. In some reviews, there were too few data to reach a firm conclusion.

Strengths of the review: We estimate the potential bias in this overview as low. We followed the Cochrane handbook for methodology (19). The search was as comprehensive as possible. Screening of studies, data extraction, and assessing the methodological quality of reviews were done in duplicate. The authors of this review are from diverse disciplines (e.g., public health, biostatistics, nutrition, physiology, and maternal and child health), and this internal diversity may be an asset of this overview.

After an extensive literature search, we did not come across any overview of SRs that has addressed this area. This overview can help healthcare providers, consumers, public health specialists, and decision makers by providing a “bird's-eye view” of the efficacy of different public health interventions across reviews and age groups.

Implications of All the Available Evidence

This overview identified interventions that had favorable effect sizes (which public health experts might contemplate using) as well as interventions that were mostly ineffective (which public health experts might want to restrict). More research is needed to assess the effect of deworming, antimalarial intervention, H. pylori treatment, and WASH intervention on anemia. Also, better recording of adverse events in primary studies is needed.

Conclusion

Results were favorable for iron and MMN fortification and supplementation with a clear reduction in the risk of anemia and increase in Hb levels across all age groups. Other interventions reported by the SRs were inconclusive and suggest further research. MMN improves outcomes better than single micronutrients. Also, better recording of adverse effects of different intervention is needed.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

AS envisioned the idea of the review. RV developed and ran the search strategies. AS and PM developed the protocol. PM and RH screened title and abstract. RH and NK screened full texts. BU resolved disagreement among primary reviewers (for screening) through discussion. AS, PM, and MK extracted data. AS and PM assessed the methodological quality of included SRs. NN, AG, and SQ provided technical advice. MK and PM drafted the manuscript with input from AS, BU, NN, AG, and SQ. All authors have contributed significantly to this overview, read the manuscript, and participated in writing and revision.

Acknowledgments

Dr. Penny Holding, Grand Challenge Canada.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2020.549549/full#supplementary-material

References

  • 1.

    KingTC. Elsevier's Integrated Pathology. (2007). p. 26389. Available online at: https://www.sciencedirect.com/science/article/pii/B9780323043281500176 (accessed December 05, 2019).

  • 2.

    WHO. The Global Prevalence of Anaemia in 2011. Geneva: World Health Organization (2015). Available online at: http://apps.who.int/iris/bitstream/10665/177094/1/9789241564960-eng.pdf?ua=1 (accessed December 05, 2019).

  • 3.

    WHO. Global Health Estimates 2014 Summary Tables: Deaths by Cause, Age and Sex, by WHO Region, 2000−2012. Geneva: World Health Organization (2014). Available online at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed December 05, 2019).

  • 4.

    BharatiSPalMChakrabartySBharatiP. Socioeconomic determinants of iron-deficiency anemia among children aged 6 to 59 months in India. Asia Pac J Public Health. (2015) 27:NP143243. 10.1177/1010539513491417

  • 5.

    SinghRKPatraS. Extent of anaemia among preschool children in EAG states, India: a challenge to policy makers. Anemia. (2014) 2014: 868752. 10.1155/2014/868752

  • 6.

    KassebaumNJJasrasariaRNaghaviMWulfSKJohnsNLozanoRet al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. (2014) 123, 61524. 10.1182/blood-2013-06-508325

  • 7.

    SolimanAKalraSSanctisV. Anemia and growth. Indian J Endocrinol Metab. (2014) 18(Suppl. 1): S15. 10.4103/2230-8210.145038

  • 8.

    JooEYKimKYKimDHLeeJ-EKimSK. Iron deficiency anemia in infants and toddlers. Blood Res. (2016) 51:268. 10.5045/br.2016.51.4.268

  • 9.

    CarterRCJacobsonJLBurdenMJArmony-SivanRDodgeNCAngelilliMLet al. Iron deficiency anemia and cognitive function in infancy. Pediatrics. (2010) 126:e42734. 10.1542/peds.2009-2097

  • 10.

    KhedrEHamedSAElbeihEEl-ShereefHAhmadYAhmedS. Iron states and cognitive abilities in young adults: neuropsychological and neurophysiological assessment. Eur Arch Psychiatry Clin Neurosci. (2008) 258:48996. 10.1007/s00406-008-0822-y

  • 11.

    LozoffB. Iron deficiency and child development. Food Nutr Bull. (2007) 28(Suppl. 4):S56071. 10.1177/15648265070284S409

  • 12.

    Lukusa KazadiANgiyuluRMGini-EhunguJLMbuyi-MuambaJMAloniMN. Factors associated with growth retardation in children suffering from sickle cell anemia: first report from central Africa. Anemia. (2017) 2017:7916348. 10.1155/2017/7916348

  • 13.

    BaltussenRKnaiCSharanM. Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world. J Nutr. (2004) 134:267884. 10.1093/jn/134.10.2678

  • 14.

    PrasannaMithraAnjuSinhaNithinKumarRameshHollaBhaskaranUnnikrishnanMahalaqua Nazli Khatibet al. Interventions for the control and prevention of anaemia among children and adolescents: an overview of systematic reviews. PROSPERO. (2016) CRD42016053687.

  • 15.

    Covidence Systematic Review Software. Melbourne, VIC: Veritas Health Innovation. Available online at: www.covidence.org (accessed December 5, 2019).

  • 16.

    LiberatiAAltmanDGTetzlaffJMulrowCGøtzschePCIoannidisJPAet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. (2009) 339:b2700. 10.1136/bmj.b2700

  • 17.

    SheaBJHamelCWellsGABouterLMKristjanssonEGrimshawJet al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. (2009) 62:101320. 10.1016/j.jclinepi.2008.10.009

  • 18.

    SheaBJReevesBCWellsGThukuMHamelCMoranJet al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. (2017) 358:j4008. 10.1136/bmj.j4008

  • 19.

    HigginsJPTGreenS. Cochrane Handbook for Systematic Reviews of Interventions. Vol. Version 5.1.0. The Cochrane Collaboration (2011). Available online at: http://handbook.cochrane.org (accessed January 02, 2019).

  • 20.

    LowMSYSpeedyJStylesCEDe-RegilLMPasrichaS-R. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. (2016) 4:CD009747. 10.1002/14651858.CD009747.pub2

  • 21.

    NeubergerAOkebeJYahavDPaulM. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. (2016) 2:CD006589. 10.1002/14651858.CD006589.pub4

  • 22.

    Mayo-WilsonEImdadAJuniorJDeanSBhuttaZA. Preventive zinc supplementation for children, and the effect of additional iron: a systematic review and meta-analysis. BMJ Open. (2014) 4:e004647. 10.1136/bmjopen-2013-004647

  • 23.

    CembranelFDallazenCGonzález-ChicaDA. [Effectiveness of ferrous sulfate supplementation in the prevention of anemia in children: a systematic literature review and meta-analysis]. Cad Saude Publica. (2013) 29:173151. 10.1590/S0102-311X2013001300014

  • 24.

    LowMFarrellABiggsB-APasrichaS-R. Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials. CMAJ. (2013) 185:E791802. 10.1503/cmaj.130628

  • 25.

    PasrichaS-RHayesEKalumbaKBiggsB-A. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. Lancet Glob Health. (2013) 1:e7786. 10.1016/S2214-109X(13)70046-9

  • 26.

    ThompsonJBiggsB-APasrichaS-R. Effects of daily iron supplementation in 2- to 5-year-old children: systematic review and meta-analysis. Pediatrics. (2013) 131:73953. 10.1542/peds.2012-2256

  • 27.

    AbdullahKKendzerskaTShahPUlerykEParkinPC. Efficacy of oral iron therapy in improving the developmental outcome of pre-school children with non-anaemic iron deficiency: a systematic review. Public Health Nutr. (2013) 16:1497506. 10.1017/S1368980012003709

  • 28.

    De-RegilLMJefferdsMEDSylvetskyACDowswellT. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. Cochrane Database Syst Rev. (2011) 2011:CD009085. 10.1002/14651858.CD009085.pub2

  • 29.

    RamakrishnanUAburtoNMcCabeGMartorellR. Multimicronutrient interventions but not vitamin a or iron interventions alone improve child growth: results of 3 meta-analyses. J Nutr. (2004) 134:2592602. 10.1093/jn/134.10.2592

  • 30.

    MatsuyamaMHarbTDavidMDaviesPSHillRJ. Effect of fortified milk on growth and nutritional status in young children: a systematic review and meta-analysis. Public Health Nutr. (2017) 20:121425. 10.1017/S1368980016003189

  • 31.

    De-RegilLMJefferdsMEDPeña-RosasJP. Point-of-use fortification of foods with micronutrient powders containing iron in children of preschool and school-age. Cochrane Database Syst Rev. (2017) 11:CD009666. 10.1002/14651858.CD009666.pub2

  • 32.

    AaronGJDrorDKYangZ. Multiple-micronutrient fortified non-dairy beverage interventions reduce the risk of anemia and iron deficiency in school-aged children in low-middle income countries: a systematic review and meta-analysis (i-iv). Nutrients. (2015) 7:384768. 10.3390/nu7053847

  • 33.

    DasJKKumarRSalamRABhuttaZA. Systematic review of zinc fortification trials. Ann Nutr Metab. (2013) 62(Suppl. 1):4456. 10.1159/000348262

  • 34.

    DasJKSalamRAKumarRBhuttaZA. Micronutrient fortification of food and its impact on woman and child health: a systematic review. Syst Rev. (2013) 2:67. 10.1186/2046-4053-2-67

  • 35.

    SalamRAMacPhailCDasJKBhuttaZA. Effectiveness of Micronutrient Powders (MNP) in women and children. BMC Public Health. (2013) 13(Suppl. 3):S22. 10.1186/1471-2458-13-S3-S22

  • 36.

    EichlerKWieserSRüthemannIBrüggerU. Effects of micronutrient fortified milk and cereal food for infants and children: a systematic review. BMC Public Health. (2012) 12:506. 10.1186/1471-2458-12-506

  • 37.

    GeraTSachdevHSBoyE. Effect of iron-fortified foods on hematologic and biological outcomes: systematic review of randomized controlled trials. Am J Clin Nutr. (2012) 96:30924. 10.3945/ajcn.111.031500

  • 38.

    De-RegilLMSuchdevPSVistGEWalleserSPeña-RosasJP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. Cochrane Database Syst Rev. (2011) 6:CD008959. 10.1002/14651858.CD008959.pub2

  • 39.

    BestCNeufingerlNDel RossoJMTranslerCvan den BrielTOsendarpS. Can multi-micronutrient food fortification improve the micronutrient status, growth, health, and cognition of schoolchildren? A systematic review. Nutr Rev. (2011) 69:186204. 10.1111/j.1753-4887.2011.00378.x

  • 40.

    DeweyKGYangZBoyE. Systematic review and meta-analysis of home fortification of complementary foods. Matern Child Nutr. (2009) 5:283321. 10.1111/j.1740-8709.2009.00190.x

  • 41.

    KristjanssonEFrancisDKLiberatoSBenkhalti JanduMWelchVBatalMet al. Food supplementation for improving the physical and psychosocial health of socio-economically disadvantaged children aged three months to five years. Cochrane Database Syst Rev. (2015) 2015:CD009924. 10.1002/14651858.CD009924.pub2

  • 42.

    McDonaghMSBlazinaIDanaTCantorABougatsosC. Screening and routine supplementation for iron deficiency anemia: a systematic review. Pediatrics. (2015) 135:72333. 10.1542/peds.2014-3979

  • 43.

    GeraTSachdevHPSNestelP. Effect of combining multiple micronutrients with iron supplementation on Hb response in children: systematic review of randomized controlled trials. Public Health Nutr. (2009) 12:75673. 10.1017/S1368980008003145

  • 44.

    GeraTSachdevHPSNestelPSachdevSS. Effect of iron supplementation on haemoglobin response in children: systematic review of randomised controlled trials. J Pediatr Gastroenterol Nutr. (2007) 44:46886. 10.1097/01.mpg.0000243440.85452.38

  • 45.

    SunJZhangLCuiJLiSLuHZhangYet al. Effect of dietary intervention treatment on children with iron deficiency anemia in China: a meta-analysis. Lipids Health Dis. (2018) 17:108. 10.1186/s12944-018-0749-x

  • 46.

    Taylor-RobinsonDCMaayanNSoares-WeiserKDoneganSGarnerP. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance. In: The Cochrane Collaboration editor. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd. (2015) 7. 10.1002/14651858.CD000371.pub6

  • 47.

    GirumTWasieA. The effect of deworming school children on anemia prevalence: a systematic review and meta-analysis. Open Nurs J. (2018) 12:15561. 10.2174/1874434601812010155

  • 48.

    HuangXQuXYanWHuangYCaiMHuBet al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. (2010) 86:2728. 10.1136/pgmj.2009.089987

  • 49.

    DangourADWatsonLCummingOBoissonSCheYVellemanYet al. Interventions to improve water quality and supply, sanitation and hygiene practices, and their effects on the nutritional status of children. Cochrane Database Syst Rev. (2013) 8:CD009382. 10.1002/14651858.CD009382.pub2

  • 50.

    AthumanMKabanywanyiAMRohwerAC. Intermittent preventive antimalarial treatment for children with anaemia. Cochrane Database Syst Rev. (2015) 1:CD010767. 10.1002/14651858.CD010767.pub2

  • 51.

    OjukwuJUOkebeJUYahavDPaulM. Oral iron supplementation for preventing or treating anaemia among children in malaria-endemic areas. Cochrane Database Syst Rev. (2009) 3:CD006589. 10.1002/14651858.CD006589.pub2

  • 52.

    OkebeJUYahavDShbitaRPaulM. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. (2011) 10:CD006589. 10.1002/14651858.CD006589.pub3

  • 53.

    DicksonRCAwasthiSDemellweekCWilliamsonPR. Anthelmintic drugs for treating worms in children: effects on growth and cognitive performance. Cochrane Database Syst Rev. (2007) 2:CD000371. 10.1002/14651858.CD000371.pub2

  • 54.

    Taylor-RobinsonDCMaayanNSoares-WeiserKDoneganSGarnerP. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance. Cochrane Database Syst Rev. (2012) 7:CD000371. 10.1002/14651858.CD000371.pub4

  • 55.

    Taylor-RobinsonDCJonesAPGarnerP. Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance. Cochrane Database Syst Rev. (2007) 4:CD000371. 10.1002/14651858.CD000371.pub3

  • 56.

    De-RegilLMSuchdevPSVistGEWalleserSPeña-RosasJP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age (review). Evid Based Child Health Cochrane Rev J. (2013) 8:112201. 10.1002/ebch.1895

  • 57.

    PachónHSpohrerRMeiZSerdulaMK. Evidence of the effectiveness of flour fortification programs on iron status and anemia: a systematic review. Nutr Rev. (2015) 73:78095. 10.1093/nutrit/nuv037

Summary

Keywords

childhood anemia, adolescent anemia, supplementation, fortification, overview of review

Citation

Mithra P, Khatib MN, Sinha AP, Kumar N, Holla R, Unnikrishnan B, Vijayamma R, Nair NS, Gaidhane A and Quazi Zahiruddin S (2021) Interventions for Addressing Anemia Among Children and Adolescents: An Overview of Systematic Reviews. Front. Pediatr. 8:549549. doi: 10.3389/fped.2020.549549

Received

06 April 2020

Accepted

18 December 2020

Published

16 February 2021

Volume

8 - 2020

Edited by

Eduardo Daniel Rosas-Blum, Texas Tech University Health Sciences Center, United States

Reviewed by

Lutfi Abdulfattah Jaber, Independent Researcher, Taibe, Israel; Denease Francis, Texas Tech University Health Sciences Center El Paso, United States; Ranjan Bista, Texas Tech University Health Sciences Center El Paso, United States

Updates

Copyright

*Correspondence: Anju Pradhan Sinha

This article was submitted to Children and Health, a section of the journal Frontiers in Pediatrics

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics